Overview
Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer
Status:
Completed
Completed
Trial end date:
2016-08-22
2016-08-22
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether chemotherapy is effective in treating women who have undergone surgery and radiation therapy for relapsed breast cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of adjuvant chemotherapy in treating women who have undergone resection for local and/or regional relapsed breast cancer.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
International Breast Cancer Study GroupCollaborator:
NSABP Foundation Inc
Criteria
DISEASE CHARACTERISTICS:- Histologically confirmed invasive breast cancer
- First local and/or regional (i.e., ipsilateral axillary or internal mammary lymph
node region) recurrence after primary treatment with mastectomy or
lumpectomy/quadrantectomy with clear surgical margins
- Local failure is defined as a tumor recurrence in any soft tissue of the
ipsilateral conserved breast or the chest wall, mastectomy scar, and/or skin
- Regional failure is defined as a tumor recurrence in the ipsilateral
axillary lymph nodes, extranodal soft tissue of the ipsilateral axilla,
and/or ipsilateral internal mammary. Regional failure does not include
supraclavicular lymph nodes or tumor in the opposite breast
- No other prior recurrence in any site, including local
- Surgical resection of the recurrence meeting 1 of the following criteria:
- Uninvolved ("clear") margins and planned radiotherapy with at least 40 Gy for
patients who had no prior adjuvant radiotherapy
- Mastectomy of the recurrence with uninvolved ("clear") margins after
lumpectomy/quadrantectomy alone for the primary
- Adjuvant trastuzumab (Herceptin®) therapy or other HER-2 directed therapies are
allowed for patients with HER-2 positive tumors and must be declared prior to
randomization
- No evidence of distant metastasis, including ipsilateral supraclavicular lymph nodes,
by x-ray or CT scan of the chest, ultrasound or CT scan of the abdomen and pelvis, or
bone scintigraphy only if alkaline phosphatase is > 2 times normal or if medically
indicated (e.g., bone pain)
- No macroscopically incomplete surgery
- No bilateral malignancy except carcinoma in situ
- No suspicious mass in the opposite breast unless that mass has been proven by biopsy
to be benign
- No skeletal pain of unknown cause
- No hot spots on bone scan for which metastases cannot be ruled out by x-ray, MRI,
and/or CT scan
- Hormone receptor status:
- Determined in the recurrent tumor by immunohistochemistry and/or ligand-binding
assay
- Estrogen receptor positive or negative
- Progesterone receptor positive or negative
PATIENT CHARACTERISTICS:
Age
- Minimum 18 years
Sex
- Female
Menopausal status
- Not specified
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- No elevated alkaline phosphatase
Renal
- Not specified
Other
- Fertile patients must use effective non-hormonal contraception
- Medically suitable for chemotherapy of 3-6 months duration
- No other primary malignant tumors except adequately treated carcinoma in situ of the
cervix or nonmelanoma skin cancer
- No non-malignant systemic disease that would preclude study treatment or prolong
follow-up
- No psychiatric or addictive disorder that would preclude giving informed consent
- No history of noncompliance to medical regimens or potential for being unreliable
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- See Disease Characteristics
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
Surgery
- See Disease Characteristics